Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma
Annals of Nuclear Medicine · 2025
DOI: 10.1007/s12149-025-02065-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Taiki Joho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan. Hauptthemen laut MEDLINE: Alpha Particles, Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: the Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan.
- Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, Japan.
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, 960-1295, Japan. zhao-s@fmu.ac.jp.
- Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
- Medical Research Center, Fukushima Medical University, Fukushima, Japan.
Förderung
- the Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake
Zitieren
APA
Joho, T., Zhao, S., Nishijima, K. I., Ukon, N., Shimoyama, S., Yamashita, A., Washino, K., Higashi, T., Kobayakawa, M., Shiga, T., Takahashi, K., & Ito, H. (2025). Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02065-0
Vancouver
Joho T, Zhao S, Nishijima KI, Ukon N, Shimoyama S, Yamashita A, et al. Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-025-02065-0
BibTeX
@article{Joho2025,
author = {Joho, Taiki and Zhao, Songji and Nishijima, Ken-Ichi and Ukon, Naoyuki and Shimoyama, Saki and Yamashita, Atsushi and Washino, Komei and Higashi, Tatsuya and Kobayakawa, Masao and Shiga, Tohru and Takahashi, Kazuhiro and Ito, Hiroshi},
title = {Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma},
journal = {Annals of Nuclear Medicine},
year = {2025},
doi = {10.1007/s12149-025-02065-0}
}
EUVIMED